IMMX Stock Overview
A clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Immix Biopharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.12 |
| 52 Week High | US$7.75 |
| 52 Week Low | US$1.75 |
| Beta | 0.17 |
| 11 Month Change | -5.78% |
| 3 Month Change | 0.47% |
| 1 Year Change | 4.43% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -42.23% |
Recent News & Updates
Recent updates
Will Immix Biopharma (NASDAQ:IMMX) Spend Its Cash Wisely?
Aug 12
Will Immix Biopharma (NASDAQ:IMMX) Spend Its Cash Wisely?
Nov 28Is Immix Biopharma (NASDAQ:IMMX) In A Good Position To Invest In Growth?
Jul 12We're Not Very Worried About Immix Biopharma's (NASDAQ:IMMX) Cash Burn Rate
Mar 29Immix Biopharma (NASDAQ:IMMX) Is In A Good Position To Deliver On Growth Plans
Sep 13We're Hopeful That Immix Biopharma (NASDAQ:IMMX) Will Use Its Cash Wisely
May 21Shareholder Returns
| IMMX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.1% | 0.9% | 0.3% |
| 1Y | 4.4% | 15.2% | 22.2% |
Return vs Industry: IMMX underperformed the US Biotechs industry which returned 13.7% over the past year.
Return vs Market: IMMX underperformed the US Market which returned 21.5% over the past year.
Price Volatility
| IMMX volatility | |
|---|---|
| IMMX Average Weekly Movement | 13.1% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: IMMX has not had significant price volatility in the past 3 months.
Volatility Over Time: IMMX's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 16 | Ilya Rachman | www.immixbio.com |
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd.
Immix Biopharma, Inc. Fundamentals Summary
| IMMX fundamental statistics | |
|---|---|
| Market cap | US$60.94m |
| Earnings (TTM) | -US$19.02m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.1x
P/E RatioIs IMMX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IMMX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$19.02m |
| Earnings | -US$19.02m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.69 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did IMMX perform over the long term?
See historical performance and comparison